Business Description
![Kiniksa Pharmaceuticals International PLC Kiniksa Pharmaceuticals International PLC logo](https://static.gurufocus.com/logos/0C0000BFNA.png?14)
Kiniksa Pharmaceuticals International PLC
NAICS : 325412
SIC : 2836
ISIN : GB00BRXB0C07
Share Class Description:
KNSA: Class ADescription
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 19.19 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.45 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 10 | |||||
Beneish M-Score | -3.17 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 49.7 | |||||
3-Year Book Growth Rate | 10.8 |
Momentum Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 77.6 | |||||
9-Day RSI | 76.32 | |||||
14-Day RSI | 74.43 | |||||
6-1 Month Momentum % | 1.7 | |||||
12-1 Month Momentum % | -8.27 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.57 | |||||
Quick Ratio | 3.16 | |||||
Cash Ratio | 2.6 | |||||
Days Inventory | 148.67 | |||||
Days Sales Outstanding | 18.39 | |||||
Days Payable | 23.87 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -0.06 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 79.31 | |||||
Operating Margin % | -8.12 | |||||
Net Margin % | -3.02 | |||||
FCF Margin % | 8.94 | |||||
ROE % | -2.41 | |||||
ROA % | -2 | |||||
ROIC % | -5.81 | |||||
ROC (Joel Greenblatt) % | -145.88 | |||||
ROCE % | -6.13 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.62 | |||||
PB Ratio | 4.27 | |||||
Price-to-Tangible-Book | 4.43 | |||||
Price-to-Free-Cash-Flow | 87.86 | |||||
Price-to-Operating-Cash-Flow | 61.53 | |||||
EV-to-EBIT | -59.62 | |||||
EV-to-EBITDA | -63.33 | |||||
EV-to-Revenue | 4.84 | |||||
EV-to-FCF | 54.11 | |||||
Price-to-Net-Current-Asset-Value | 9.6 | |||||
Price-to-Net-Cash | 16.64 | |||||
Earnings Yield (Greenblatt) % | -1.68 | |||||
FCF Yield % | 1.15 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:KNSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiniksa Pharmaceuticals International PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 338.93 | ||
EPS (TTM) ($) | -0.16 | ||
Beta | 0.18 | ||
Volatility % | 44.73 | ||
14-Day RSI | 74.43 | ||
14-Day ATR ($) | 1.220363 | ||
20-Day SMA ($) | 21.15425 | ||
12-1 Month Momentum % | -8.27 | ||
52-Week Range ($) | 14.12 - 27.88 | ||
Shares Outstanding (Mil) | 71.08 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Kiniksa Pharmaceuticals International PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Kiniksa Pharmaceuticals International PLC Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Kiniksa Pharmaceuticals International PLC Frequently Asked Questions
What is Kiniksa Pharmaceuticals International PLC(KNSA)'s stock price today?
The current price of KNSA is $26.12. The 52 week high of KNSA is $27.88 and 52 week low is $14.12.
When is next earnings date of Kiniksa Pharmaceuticals International PLC(KNSA)?
The next earnings date of Kiniksa Pharmaceuticals International PLC(KNSA) is 2024-10-31 Est..
Does Kiniksa Pharmaceuticals International PLC(KNSA) pay dividends? If so, how much?
Kiniksa Pharmaceuticals International PLC(KNSA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |